What are the nicotinic signs of organophosphate poisoning?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nicotinic Signs of Organophosphate Poisoning

The nicotinic signs of organophosphate poisoning include muscle fasciculations, muscle weakness progressing to flaccid paralysis, tachycardia, hypertension, mydriasis, and respiratory muscle paralysis. 1

Mechanism and Clinical Presentation

Organophosphate poisoning causes acetylcholinesterase inhibition, leading to acetylcholine accumulation at nicotinic receptors located at the neuromuscular junction and autonomic ganglia. This nicotinic overstimulation produces distinct clinical effects that differ from the muscarinic manifestations 2.

Specific Nicotinic Manifestations

Musculoskeletal System

  • Involuntary fasciculations (muscle twitching) - often the earliest nicotinic sign, particularly with dermal exposure 1
  • Progressive muscle weakness
  • Flaccid paralysis - results from depolarizing neuromuscular blockade 2, 1
  • Fasciculations typically progress to complete paralysis as the constant nicotinic receptor activation causes depolarization block 1

Cardiovascular System

  • Initial tachycardia and hypertension - due to nicotinic sympathetic ganglia hyperstimulation 1
  • This occurs early, before the later muscarinic effects of bradycardia and hypotension develop 1

Respiratory System

  • Respiratory muscle paralysis - the most life-threatening nicotinic effect 1
  • This paralysis, combined with CNS respiratory depression, is the primary cause of death in severe poisoning 1

Ocular

  • Mydriasis (pupil dilation) - though less common than the muscarinic miosis 2, 3

Route-Dependent Presentation

The route of exposure influences which nicotinic signs appear first:

  • Vapor/inhalational exposure: Respiratory symptoms (muscarinic) predominate initially, with nicotinic muscle weakness developing later 1
  • Dermal exposure: Early local muscle twitching and fasciculations (nicotinic) are prominent, with more gradual progression to systemic effects 1

Critical Clinical Distinction

Atropine does NOT reverse nicotinic effects - it only treats muscarinic manifestations 2, 1. The nicotinic neuromuscular paralysis requires oxime therapy (pralidoxime) when administered early, before enzyme "aging" occurs 2. This is a critical pitfall: adequate atropinization may resolve bronchorrhea and bradycardia, but the patient can still die from nicotinic-mediated respiratory muscle paralysis if oximes are not given.

Electrophysiological Findings

Nicotinic dysfunction produces characteristic neurophysiological abnormalities 4, 5:

  • Repetitive responses to single supramaximal stimulation
  • Decrement-increment pattern with high-frequency (30 Hz) repetitive nerve stimulation
  • These findings correlate with severity of clinical nicotinic manifestations

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.